ArticleBMC veterinary research2025
Evaluation of the therapeutic effect of Berberine microcapsules on Salmonella enteritidis-infected mice.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An Updated and Comprehensive Review ofMolecules (Basel, Switzerland) · 2026Review
- Amorphous solid dispersions as a strategy to enhance the bioavailability and stability of formulations containing plant active ingredients: An integrative review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundBerberine (BBR) is an alkaloid derived from traditional Chinese herbal remedies, like Huanglian and Huangbai. It possesses a range of anti-inflammatory properties but is known to cause significant irritation upon injection and has a poor taste when consumed orally, with limited absorption into the body. Berberine microcapsules (BBR-M) were developed using solid dispersion (SD) and microcapsule technology for a Salmonella enteritidis-infected mouse enteritis model experiment to test their efficacy in regulating Salmonella enteritidis by analyzing RT- qPCR testing results, alongside 16 S rDNA sequencing data and immunohistochemistry analysis to determine the dosage and mechanism of action of BBR-M.
resultsThe results demonstrated that BBR-M exhibited good intestinal sustained-release characteristics and storage stability. Each dose of BBR-M could alleviate intestinal injury, modulating immunoglobulin profiles and differentially regulating pro-inflammatory (IL-6, IL-1β, TNF-α) and anti-inflammatory (IL-10) cytokine expression; particularly at the 40 mg/kg dosage, it significantly restored microbial homeostasis through selective reduction of enteropathogens (Escherichia coli, Shigella, Klebsiella, Salmonella) and enrichment of commensal probiotics (Akkermansia muciniphila).
conclusionsCollectively, these findings position the medium-dose BBR-M regimen as a promising therapeutic candidate for Salmonella enteritidis enteritis intervention, demonstrating optimal efficacy in pathogen clearance, inflammatory modulation, and intestinal barrier restoration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.